After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration
→ About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with Bausch Health’s Salix Pharmaceuticals to develop the late-stage oral compound, which targets the sphingosine 1-phosphate (S1P) receptor that is understood to play a role in autoimmune diseases, such as IBD and ulcerative colitis. Financial details of the deal were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.